Stock code: 688202 Stock abbreviation: Medicilon Announcement No.: 2025-005

Shanghai Medicililon Biopharmaceutical Co., Ltd

Announcement on the election of the chairman of the board of directors, the chairman of the board of supervisors, members of the special committees of the board of directors, and the appointment of senior management personnel and securities affairs representatives

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Medicilon") is located in:

On January 13, 2025, the first extraordinary general meeting of shareholders in 2025 and the first employee representatives in 2025 were held

At the General Assembly, all members of the fourth board of directors and the fourth board of supervisors of the company were elected for a term of three years from the date of deliberation and approval of the first extraordinary general meeting of shareholders in 2025.

On January 13, 2025, the company held the first meeting of the fourth board of directors and deliberated and approved the "Guan

Proposal on the election of the chairman of the fourth board of directors of the company, "proposal on the election of members of the special committee of the fourth board of directors of the company", "proposal on the appointment of the general manager of the company", "proposal on the appointment of the deputy general manager of the company", "proposal on the appointment of the company's financial director", "proposal on the appointment of the secretary of the board of directors of the company" and "proposal on the appointment of the company's securities affairs representative"; The first meeting of the fourth board of supervisors was held, and the "Proposal on Electing the Chairman of the Fourth Board of Supervisors of the Company" was deliberated and approved. The specific situation is hereby announced as follows:

1. Elect the chairman of the fourth board of directors of the company

The members of the fourth board of directors of the company have been elected at the company's first extraordinary general meeting of shareholders in 2025. In accordance with the provisions of the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law") and the Articles of Association

On January 13, 2025, the Company held the first meeting of the fourth session of the Board of Directors to elect CHUN-LIN

MR. CHEN IS THE CHAIRMAN OF THE FOURTH BOARD OF DIRECTORS OF THE COMPANY, AND HIS TERM OF OFFICE IS FROM THE DATE OF DELIBERATION AND APPROVAL OF THE FIRST MEETING OF THE FOURTH BOARD OF DIRECTORS TO THE DATE OF EXPIRATION OF THE TERM OF THE FOURTH BOARD OF DIRECTORS.

Announcement on the General Election of the Board of Directors and the Board of Supervisors (Announcement No.: 2024-060).

2. Elect the chairman of the fourth board of supervisors of the company

The members of the fourth board of supervisors of the company have been elected by the company's first extraordinary general meeting of shareholders in 2025 and the first employee representative meeting in 2025. In accordance with the provisions of the Company Law and the Articles of Association, on January 13, 2025, the Company held the first meeting of the fourth board of supervisors and elected Mr. Jiang Pin as the chairman of the fourth board of supervisors of the company, with a term of office from the date of deliberation and approval of the first meeting of the fourth board of supervisors to the date of expiration of the term of office of the fourth board of supervisors.

The resume of Mr. Jiang Pin is detailed in the Company's disclosure on the website of the Shanghai Stock Exchange on January 14, 2025

(www.sse.com.cn) Announcement of Shanghai Medicilon Biopharmaceutical Co., Ltd. on the Election of Employee Representative Supervisors of the Fourth Board of Supervisors (Announcement No.: 2025-006).

3. Elect members of the special committee of the fourth board of directors of the company

In accordance with the Company Law, the Articles of Association and other relevant regulations, the fourth session of the Board of Directors of the Company has four committees, namely: Audit Committee, Nomination Committee, Strategy Committee, Remuneration and Appraisal Committee. After the election, the composition of the special committee of the fourth board of directors of the company is as follows:

1. Audit Committee: Ms. Wang Jianfeng, Mr. Lai Weidong and Mr. Chen Yonghang, of which Ms. Wang Jianfeng, an independent director, is the chairman.

2. NOMINATION COMMITTEE: MR. MA DAWEI, MR. LAI WEIDONG, MR. CHUN-LIN CHEN, OF WHICH MR. MA DAWEI, AN INDEPENDENT DIRECTOR, IS THE CHAIRMAN OF THE COMMITTEE.

3. STRATEGIC COMMITTEE: MR. CHUN-LIN CHEN, MR. MA DAWEI, MR. CHEN GUOKAI, OF WHICH MR. CHUN-LIN CHEN IS THE CHAIRMAN.

4. Remuneration and Appraisal Committee: Mr. Lai Weidong, Ms. Wang Jianfeng, Mr. Chen Guokai, of which Mr. Lai Weidong, an independent director, is the chairman.

The Audit Committee, the Nomination Committee, and the Remuneration and Appraisal Committee are all independent directors, and the independent directors serve as the chairmen. None of the members of the audit committee are senior managers of the company, and the chairman of the committee, Ms. Wang Jianfeng, is an accounting professional. The term of office of the special committees of the fourth board of directors of the company is three years, from the date of deliberation and approval of the first meeting of the fourth board of directors to the date of expiration of the term of the fourth board of directors.

The biographies of the above personnel are detailed in the Company's disclosure on the website of the Shanghai Stock Exchange on December 25, 2024

(www.sse.com.cn) Announcement of Shanghai Medicilon Biopharmaceutical Co., Ltd. on the General Election of the Board of Directors and Board of Supervisors of the Company (Announcement No.: 2024-060).

Fourth, the appointment of the general manager of the company

IN ORDER TO PROMOTE THE NORMAL AND ORDERLY PROGRESS OF THE COMPANY'S WORK, IN ACCORDANCE WITH THE PROVISIONS OF THE COMPANY LAW AND RELATED LAWS, ADMINISTRATIVE REGULATIONS, NORMATIVE DOCUMENTS AND THE ARTICLES OF ASSOCIATION, THE BOARD OF DIRECTORS OF THE COMPANY AGREED TO CONTINUE TO APPOINT MR. CHUN-LIN CHEN AS THE GENERAL MANAGER OF THE COMPANY FOR A TERM OF THREE YEARS, FROM THE DATE OF DELIBERATION AND APPROVAL OF THE FIRST MEETING OF THE FOURTH BOARD OF DIRECTORS TO THE DATE OF EXPIRATION OF THE TERM OF OFFICE OF THE FOURTH BOARD OF DIRECTORS.

THE CURRICULUM VITAE OF MR. CHUN-LIN CHEN IS DETAILED IN THE COMPANY'S DISCLOSURE ON THE SHANGHAI STOCK EXCHANGE ON DECEMBER 25, 2024

"Announcement of Shanghai Medicilon Biopharmaceutical Co., Ltd. on the General Election of the Board of Directors and Board of Supervisors of the Company" (Announcement No.: 2024-060) on the website (www.sse.com.cn).

5. Appointment of deputy general manager of the company

In accordance with the "Company Law", "Articles of Association" and other relevant regulations, the general manager CHUN-LIN CHEN first

The board of directors of the company agreed to appoint Mr. Hu Jianglin as the executive deputy general manager of the company, and Ms. Cai Jinna, Mr. QINGCONG LIN, Mr. Chen Guokai, Mr. Luo Jialiang and Ms. Liu Binbin as the deputy general managers of the company for a term of three years, from the date of deliberation and approval of the first meeting of the fourth board of directors to the date of expiration of the term of the fourth board of directors.

The biographies of Mr. QINGCONG LIN, Ms. Cai Jinna and Mr. Chen Guokai can be found in the company's 2024 year

On December 25, the "Announcement of Shanghai Medicilon Biopharmaceutical Co., Ltd. on the General Election of the Board of Directors and the Board of Supervisors of the Company" (Announcement No.: 2024-060) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn), the resumes of Mr. Hu Jianglin, Mr. Luo Jialiang and Ms. Liu Binbin are detailed in the annex to the announcement.

6. Appoint the person in charge of finance of the company

In accordance with the "Company Law", "Articles of Association" and other relevant regulations, the general manager CHUN-LIN CHEN first

The Board of Directors of the Company agreed to appoint Ms. Zhang Donghua as the Chief Financial Officer of the Company for a term of three years, from the date of deliberation and approval of the first meeting of the fourth board of directors to the date of expiration of the term of office of the fourth board of directors. Ms. Zhang Donghua's resume is attached to the announcement

Item.

7. Appointment of the secretary of the board of directors of the company

In accordance with the "Company Law", "Articles of Association" and other relevant provisions, nominated by the chairman of the board of directors and approved by the nomination committee of the board of directors of the company, the board of directors of the company agreed to appoint Ms. Zhuo Nan as the secretary of the board of directors of the company for a term of three years, from the date of deliberation and approval of the first meeting of the fourth board of directors to the date of expiration of the term of office of the fourth board of directors. Ms. Zhuo Nan's resume is attached to the announcement.

8. Appointment of the company's securities affairs representative

In accordance with the "Company Law", "Articles of Association" and other relevant provisions, the board of directors of the company agreed to appoint Mr. Weng Shaofan as the company's securities affairs representative to assist the secretary of the board of directors in carrying out daily work for a term of three years, from the date of deliberation and approval of the first meeting of the fourth board of directors to the date of expiration of the term of office of the fourth board of directors. Mr. Weng Shaofan's resume is detailed in the attachment of the announcement.

9. Contact information of the secretary of the board of directors and securities affairs representatives

Address: No. 585, Chuanda Road, Pudong New Area, Shanghai

Contact number: 021-58591500*8818

E-mail: IR@medicilon.com.cn

The announcement is hereby made.

Board of Directors of Shanghai Medicilon Biopharmaceutical Co., Ltd

January 14, 2025

Annex:

1. Resumes of some senior managers

Mr. Hu Jianglin, born in 1970, Chinese nationality, no right of permanent residence abroad, postgraduate degree.

He has successively served as vice president and president of listed companies such as Shanghai Jiaotong University Onlly Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai Guijiu Co., Ltd., Guoxuan Hi-Tech Co., Ltd., chairman and general manager of Shanghai Sunwin Chuangying Equity Investment Fund Management Co., Ltd., and managing partner of Shanghai Yongzheng Investment Holding Group Co., Ltd., etc., and has rich experience in enterprise operation management and capital operation. He joined Medicilon in October 2024 and is currently the company's executive deputy general manager, co-CEO, chief strategic development officer and president of its subsidiary, Medicipro.

As of the disclosure date of this announcement, Mr. Hu Jianglin does not hold shares of the company, has no relationship with other directors, supervisors, senior management of the company, shareholders and actual controllers holding more than 5% of the company's shares, does not exist in the form of not being allowed to serve as a senior manager, has not been punished by the China Securities Regulatory Commission and other departments and disciplined by the stock exchange, has not been investigated by the judicial authorities for suspected crimes or has been investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, is not a dishonest person subject to execution, in accordance with relevant laws, Qualifications required by administrative regulations, departmental rules, normative documents, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.

Mr. Luo Jialiang, born in 1965, Chinese nationality, no right of permanent residence abroad, doctoral candidate.

He used to be the Director of Operations of Shanghai Pfizer Pharmaceutical Co., Ltd., the Director of the Pharmaceutical Division of Lonza (China) Investment Co., Ltd. in China, the Vice President of Operations of Shandong Buchang Pharmaceutical Co., Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd

Deputy General Manager, Global CEO of iMax/Hovione Holding Co., Ltd, etc. Dr. Yu is internationally renowned

He has extensive experience in the management of pharmaceutical companies, and has rich experience in quality and production system improvement. He joined Medicilon in September 2024 and is currently the company's Deputy General Manager, Chief Operating Officer and Senior Vice President of Pharmaceutical Research.

As of the disclosure date of this announcement, Mr. Luo Jialiang does not hold shares of the company, has no relationship with other directors, supervisors, senior managers of the company, shareholders and actual controllers holding more than 5% of the company's shares, does not have the situation of not being prohibited from serving as senior management, has not been punished by the China Securities Regulatory Commission and other departments and disciplined by the stock exchange, has not been investigated by the judicial authorities for suspected crimes or suspected of violations of laws and regulations by the China Securities Regulatory Commission, is not a dishonest person subject to execution, in accordance with relevant laws, Qualifications required by administrative regulations, departmental rules, normative documents, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.

Ms. Liu Binbin, born in 1977, Chinese nationality, no right of permanent residence abroad, postgraduate degree,

China Europe International Business School Executive Diploma. He used to be the deputy manager of the finance department of COFCO Oil (Longkou) Co., Ltd., the project manager of the investment department of Zeyang Investment Consulting (Shanghai) Co., Ltd., and the chief financial officer of Shanghai Xinxiyuan Investment Management Group Co., Ltd., joined the company in September 2016, served as the company's chief financial officer, and is currently the company's deputy general manager and vice president of operations.

As of the disclosure date of this announcement, Ms. Liu Binbin held 20,730 shares of the Company, together with other directors of the Company

There is no relationship between the company, supervisors, senior management personnel and shareholders and actual controllers holding more than 5% of the company's shares, there is no situation where they are not allowed to serve as senior managers, they have not been punished by the China Securities Regulatory Commission and other departments and disciplined by the stock exchange, they have not been investigated by the judicial authorities for suspected crimes or have been investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, they are not dishonest judgment debtors, and they comply with relevant laws, administrative regulations, departmental rules, normative documents, and Qualifications required by the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.

Ms. Zhang Donghua, born in 1985, Chinese nationality, no right of permanent residence abroad, bachelor degree.

He has successively served as the financial manager of CTI Testing and Certification Group Co., Ltd., the financial manager of Shanghai Hufang Software Co., Ltd., the financial manager of Shanghai 2345 Network Technology Co., Ltd., and the financial director of Puyan (Shanghai) Standard Technical Service Co., Ltd. He joined Medicilon in October 2019 and served as the deputy director of corporate finance and is currently the head of corporate finance, responsible for the overall work of corporate finance.

As of the disclosure date of this announcement, Ms. Zhang Donghua does not hold shares of the company, has no relationship with other directors, supervisors, senior managers of the company, shareholders and actual controllers holding more than 5% of the company's shares, does not have the situation of not being allowed to serve as senior management, has not been punished by the China Securities Regulatory Commission and other departments and disciplined by the stock exchange, has not been investigated by the judicial authorities for suspected crimes or suspected of violations of laws and regulations by the China Securities Regulatory Commission, is not a dishonest person subject to execution, in accordance with relevant laws, Qualifications required by administrative regulations, departmental rules, normative documents, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.

Ms. Zhuo Nan, born in 1992, Chinese nationality, no permanent right of abode abroad, postgraduate degree,

Graduated from The University of Sydney with a degree in Finance. He joined the United States in August 2017

Dixi, participated in the whole process of the listing of Medicilon's IPO project. Former manager of the company's securities office,

The securities affairs representative, currently the secretary of the board of directors of the company, obtained the qualification certificate of secretary of the board of directors of the Science and Technology Innovation Board issued by the Shanghai Stock Exchange in October 2019, and has relevant professional capabilities, and his qualifications meet the relevant provisions of the "Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange".

As of the disclosure date of this announcement, Ms. Zhuo Nan does not hold shares of the company, has no relationship with other directors, supervisors, senior managers of the company, shareholders and actual controllers holding more than 5% of the company's shares, does not have the situation of not being allowed to serve as senior management, has not been punished by the China Securities Regulatory Commission and other departments and disciplined by the stock exchange, has not been investigated by the judicial authorities for suspected crimes or suspected of violating laws and regulations by the China Securities Regulatory Commission, is not a dishonest person subject to execution, in accordance with relevant laws, Qualifications required by administrative regulations, departmental rules, normative documents, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.

2. Curriculum vitae of securities affairs representatives

Mr. Weng Shaofan, born in 1995, Chinese nationality, no permanent right of abode abroad, bachelor degree.

He joined Medicilon in February 2021 and served as the assistant to the company's securities affairs representative and head of securities affairs, and is currently the company's securities affairs representative, and obtained the qualification certificate of secretary of the board of directors of the Science and Technology Innovation Board issued by the Shanghai Stock Exchange in April 2021.

As of the disclosure date of this announcement, Mr. Weng Shaofan does not hold shares of the company, and there is no relationship between other directors, supervisors, senior managers of the company, shareholders and actual controllers who hold more than 5% of the company's shares, has not been punished by the China Securities Regulatory Commission and other departments and disciplinary actions of the stock exchange, has not been investigated by the judicial authorities for suspected crimes or suspected of violations of laws and regulations by the China Securities Regulatory Commission, is not a dishonest person subject to execution, in line with relevant laws, administrative regulations, departmental rules, normative documents, Qualifications required by the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other regulations of the Exchange.